A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the Treatment of Advanced Solid Tumors With PTEN Loss or Low Expression
Convalife (Shanghai) Co., Ltd.
Convalife (Shanghai) Co., Ltd.
University of California, Irvine
Daiichi Sankyo
HealthPartners Institute
Stanford University
Mayo Clinic
University of Washington
City of Hope Medical Center
Tempus AI
Brown University
British Columbia Cancer Agency
Washington University School of Medicine
University of California, Irvine
Tongji Hospital
Elevation Oncology
Optimal Health Research
Actuate Therapeutics Inc.
Dana-Farber Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Zhejiang Provincial People's Hospital
Erasmus Medical Center
pharmaand GmbH
Wake Forest University Health Sciences
DEKK-TEC, Inc.
MetiMedi Pharmaceuticals
Sun Yat-sen University
Tetra Bio-Pharma
National Institutes of Health Clinical Center (CC)
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Amgen
AIO-Studien-gGmbH
Cornerstone Pharmaceuticals
Alliance for Clinical Trials in Oncology
Memorial Sloan Kettering Cancer Center
Jonsson Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Massachusetts General Hospital
Associazione Oncologia Traslazionale
Hellenic Cooperative Oncology Group
Sheba Medical Center
GE Healthcare
Pharmacyclics LLC.
National Cancer Institute (NCI)
Schillerhoehe Hospital
Novartis
University of Alabama at Birmingham
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Siemens Molecular Imaging